Somnomed Limited (AU:SOM) has released an update.
SomnoMed, a leader in oral appliance solutions for obstructive sleep apnea (OSA), has announced significant market potential with over 900 million individuals affected by OSA globally and advancements in Rest Assure®, a tech-enabled oral device. The company has also successfully raised $22.6 million to boost capital flexibility and fund strategic growth initiatives.
For further insights into AU:SOM stock, check out TipRanks’ Stock Analysis page.
